Redondo, S, Esquirol, A, Novelli, S, Caballero, AC, Garrido, A, Onate, G, Lopez, J, Moreno, C, Saavedra, SD, Granell, M, Briones, J, Sierra, J, Martino, R, Garcia-Cadenas, I. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. Transplantation And Cellular Therapy. 2022; 28(1)DOI:10.1016/j.jtct.2021.10.015. PMID:34757054. IF:3.200(Q2/5D).

Redondo, S, Garcia-Cadenas, I, Esquirol, A, Portos, JM, Iranzo, E, Arguello-Tomas, M, Saavedra, S, Oñate, G, Caballero, AC, Garrido, A, López, J, Muntañola, A, Paviglianiti, A, Miqueleiz, S, Sierra, J, Briones, J, Martino, R. Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation. EUROPEAN JOURNAL OF HAEMATOLOGY. 2024; 113(6)DOI:10.1111/ejh.14294. PMID:39155459. IF:2.300(Q2/5D).

Esquirol, A, Pascual, MJ, Montoro, J, Piñana, JL, Ferrà, C, Herruzo, B, Garcia-Cadenas, I, Balaguer, A, Perez, A, Huguet, M, Redondo, S, Villalba, M, Hernandez-Boluda, JC, Chorao, P, Hernani, R, Sanz, J, Solano, C, Sierra, J, Martino, R. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil. Transplantation And Cellular Therapy. 2024; 30(10)DOI:10.1016/j.jtct.2024.07.027. PMID:39116938. IF:4.400(Q1/1D).

Salas, MQ, Cascos, E, López-García, A, Pérez-López, E, Baile-González, M, López-Corral, L, Cascón, MJP, Luque, M, Esquirol, A, Fernando, IH, Ormtegi, IO, Marin, AJS, Peña-Muñóz, F, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Girón, MFD, Pinedo, LG, González-Rodríguez, AP, Torrado, T, García, L, Filaferro, S, Cedillo, A, Basalobre, P, Ortí, G, Chacón, MJ. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC. BONE MARROW TRANSPLANTATION. 2024; 59(12)DOI:10.1038/s41409-024-02414-z. PMID:39277653. IF:5.200(Q1/1D).

Piñana, JL, Giménez, E, Vázquez, L, Marcos, MA, Guerreiro, M, Duarte, R, Pérez, A, de Miguel, C, Espigado, I, González-Vicent, M, Suarez-Lledó, M, García-Cadenas, I, Martino, R, Cedillo, A, Rovira, M, de la Cámara, R, Navarro, D, Solano, C. Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC). Mediterranean Journal of Hematology and Infectious Diseases. 2024; 16(1)DOI:10.4084/MJHID.2024.065. PMID:39258183. IF:1.500(Q3/8D).

Fox, ML, García-Cadenas, I, Navarro, V, Martínez, AP, Kara, M, Bazán, IS, Coll, CF, Bailén, R, Bento, L, Parody, R, Esquirol, A, Orti, G, Mussetti, A, Salamero, O, Martino, R, González, AP, Barba, P, Kwon, M, Solano, C, Bosch, F, Valcárcel, D. Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies. BONE MARROW TRANSPLANTATION. 2024; 59(10)DOI:10.1038/s41409-024-02322-2. PMID:38914883. IF:5.200(Q1/1D).